117 related articles for article (PubMed ID: 38554525)
1. Construction of aptamer-siRNA chimera and glutamine modified carboxymethyl-β-cyclodextrin nanoparticles for the combination therapy against lung squamous cell carcinoma.
Hao Y; Yang J; Liu D; Zhang H; Ou T; Xiao L; Chen W
Biomed Pharmacother; 2024 May; 174():116506. PubMed ID: 38554525
[TBL] [Abstract][Full Text] [Related]
2. Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymerpolyethylenimine to improve oral squamous carcinoma treatment.
Wang D; Xu X; Zhang K; Sun B; Wang L; Meng L; Liu Q; Zheng C; Yang B; Sun H
Int J Nanomedicine; 2018; 13():187-198. PubMed ID: 29343957
[TBL] [Abstract][Full Text] [Related]
3. Glutamine-β-cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2.
Zhou P; Liang X; Zhou C; Qin J; Hou C; Zhu Z; Zhang W; Wang S; Zhong D
J Mater Chem B; 2019 Sep; 7(35):5363-5375. PubMed ID: 31403158
[TBL] [Abstract][Full Text] [Related]
4. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
[TBL] [Abstract][Full Text] [Related]
6. Au-siRNA@ aptamer nanocages as a high-efficiency drug and gene delivery system for targeted lung cancer therapy.
Yang Y; Han Y; Sun Q; Cheng J; Yue C; Liu Y; Song J; Jin W; Ding X; de la Fuente JM; Ni J; Wang X; Cui D
J Nanobiotechnology; 2021 Feb; 19(1):54. PubMed ID: 33627152
[TBL] [Abstract][Full Text] [Related]
7. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
[TBL] [Abstract][Full Text] [Related]
8. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
9. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
[TBL] [Abstract][Full Text] [Related]
10. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
11. Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-β-cyclodextrin nanocarrier.
Li JM; Zhang W; Su H; Wang YY; Tan CP; Ji LN; Mao ZW
Int J Nanomedicine; 2015; 10():3147-62. PubMed ID: 25960653
[TBL] [Abstract][Full Text] [Related]
12. Construction of Durvalumab/carbon nanotube/PEI/aptamer-siRNA chimera for the immunotherapy of hepatocellular carcinoma.
Qiang N; Wei L; Tao Y; Jin W; Bin Y; DingHua Z
Biomed Mater; 2022 Feb; 17(2):. PubMed ID: 35147513
[TBL] [Abstract][Full Text] [Related]
13. Radiotherapy-induced enrichment of EGF-modified doxorubicin nanoparticles enhances the therapeutic outcome of lung cancer.
Wang J; Zhang Y; Zhang G; Xiang L; Pang H; Xiong K; Lu Y; Li J; Dai J; Lin S; Fu S
Drug Deliv; 2022 Dec; 29(1):588-599. PubMed ID: 35156493
[TBL] [Abstract][Full Text] [Related]
14. Functionalized selenium nanoparticles for targeted delivery of doxorubicin to improve non-small-cell lung cancer therapy.
Xia Y; Chen Y; Hua L; Zhao M; Xu T; Wang C; Li Y; Zhu B
Int J Nanomedicine; 2018; 13():6929-6939. PubMed ID: 30464451
[TBL] [Abstract][Full Text] [Related]
15. A dual-functional HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells.
Shen Y; Li M; Liu T; Liu J; Xie Y; Zhang J; Xu S; Liu H
Int J Nanomedicine; 2019; 14():4029-4044. PubMed ID: 31213813
[No Abstract] [Full Text] [Related]
16. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
[TBL] [Abstract][Full Text] [Related]
17. Construction of PEI-EGFR-PD-L1-siRNA dual functional nano-vaccine and therapeutic efficacy evaluation for lung cancer.
Yang G; Zhou D; Dai Y; Li Y; Wu J; Liu Q; Deng X
Thorac Cancer; 2022 Nov; 13(21):2941-2950. PubMed ID: 36117149
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Lysosomal Escape of pH-Responsive Polyethylenimine-Betaine Functionalized Carbon Nanotube for the Codelivery of Survivin Small Interfering RNA and Doxorubicin.
Cao Y; Huang HY; Chen LQ; Du HH; Cui JH; Zhang LW; Lee BJ; Cao QR
ACS Appl Mater Interfaces; 2019 Mar; 11(10):9763-9776. PubMed ID: 30776886
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
[TBL] [Abstract][Full Text] [Related]
20. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]